Patents Assigned to Cytosorbent, Inc.
  • Patent number: 12280196
    Abstract: Provided herein are materials and methods of reducing contamination in a biological substance or treating contamination in a subject by one or more toxins comprising contacting the biological substance with an effective amount of a sorbent capable of sorbing the toxin, wherein the sorbent comprises a plurality of pores ranging from 50 ? to 40,000 ? with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and sorbing the toxin. Also provided are kits to reduce contamination by one or more toxins in a biological substance comprising a sorbent capable of sorbing a toxin, wherein the sorbent comprises a plurality of pores ranging from 50 ? to 40,000 ? with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and a vessel to store said sorbent when not in use together with packaging for same.
    Type: Grant
    Filed: August 30, 2022
    Date of Patent: April 22, 2025
    Assignee: CytoSorbents, Inc.
    Inventors: Phillip P. Chan, Vincent J. Capponi, Thomas D. Golobish, Humayra Begum Ali
  • Patent number: 12208116
    Abstract: The invention concerns biocompatible polymer systems comprising at least one polymer with a plurality of pores, said polymer comprising a sulfonic acid salt functionality designed to adsorb a broad range of protein based toxins from less than 0.5 kDa to 1,000 kDa and positively charged ions including but not limited to potassium.
    Type: Grant
    Filed: June 30, 2023
    Date of Patent: January 28, 2025
    Assignee: CytoSorbents, Inc.
    Inventors: Thomas Golobish, Maryann Gruda, Tamaz Guliashvili, Pamela O'Sullivan, Andrew Scheirer, Vi Dan, Wei-Tai Young, Vincent Capponi, Phillip Chan
  • Patent number: 12121879
    Abstract: The invention concerns polymeric media based on modified natural polysaccharides for removing one or both of Anti-A Antibodies and Anti-B Antibodies from human blood or plasma, the media comprising one or both of (i) a polymeric solid support with a blood group A Antigen ligand attached to the solid support at a ligand loading between 1-5 mg/mL of solid support, and wherein the media is stable under physiological pH conditions, and (ii) a polymeric solid support with a blood group B Antigen ligand attached to the solid support at a ligand loading between 1-5 mg/mL of solid support, and wherein the media is stable under physiological pH conditions.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: October 22, 2024
    Assignee: CytoSorbents, Inc.
    Inventors: Tamaz Guliashvili, Maryann Gruda, Thomas Golobish, David James, Karl-Gustav Ruggeberg, Pamela O'Sullivan, Sarah Patterson
  • Patent number: 12076474
    Abstract: The present invention concerns methods of treating a patient suffering from a traumatic brain injury (TBI), comprising contacting said patient's blood with a sorbent for an inflammatory mediator and kits for performing such treatments.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: September 3, 2024
    Assignee: CytoSorbents, Inc.
    Inventor: Phillip Chan
  • Patent number: 9604196
    Abstract: A size-selective hemocompatible porous polymeric adsorbent system is provided, the polymer system comprises at least one crosslinking agent and at least one dispersing agent, and the polymer has a plurality of pores with diameters in the range from about 17 to about 40,000 Angstroms.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: March 28, 2017
    Assignee: Cytosorbent, Inc.
    Inventors: Wei-Tai Young, Robert L. Albright, Thomas D. Golobish, Vincent Capponi, Philip Chan
  • Patent number: 8349550
    Abstract: Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of pro-inflammatory or anti-inflammatory stimulators or mediators. The devices, systems, and methods serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: January 8, 2013
    Assignees: Cytosorbents, Inc.
    Inventors: James A Brady, James F Winchester, Vadim Davankov, Maria Tsvurupa, Ludmila Pavlova, Frank M Norris, Peter J Quartararo, Jr., Jamie A Salsberg
  • Patent number: 8334094
    Abstract: Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of pro-inflammatory or anti-inflammatory stimulators or mediators. The devices, systems, and methods serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: December 18, 2012
    Assignees: Cytosorbents, Inc.
    Inventors: James A Brady, James F Winchester, Vadim Davankov, Maria Tsyurupa, Ludmila Pavlova, Frank M Norris, Peter Quartararo, Jr., Jamie A Salsberg
  • Patent number: 8329388
    Abstract: Devices, systems, and methods reduce levels of proinflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among proinflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of proinflammatory or anti-inflammatory stimulators or mediators. The devices, systems, and methods serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among proinflammatory or anti-inflammatory stimulators or mediators.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: December 11, 2012
    Assignees: Cytosorbents, Inc.
    Inventors: James A Brady, James F Winchester, Vadim Davankov, Maria Tsvurupa, Ludmila Pavlova, Frank M Norris, Peter J Quartararo, Jr., Jamie A Salsberg
  • Patent number: 8211310
    Abstract: A size-selective hemocompatible porous polymeric adsorbent system is provided, the polymer system comprises at least one polymer with a plurality of pores, and the polymer has at least one transport pore with a diameter from about 250 Angstroms to about 2000 Angstroms, and the polymer has a transport pore volume greater than about 1.8% to about 78% of a capacity pore of volume of the polymer.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: July 3, 2012
    Assignee: Cytosorbents, Inc.
    Inventors: Wei-Tai Young, Robert L. Albright, Thomas D. Golobish, Vincent Capponi, Philip Chan
  • Patent number: 7875182
    Abstract: Size-selective hemocompatible porous polymeric adsorbents are provided with a pore structure capable of excluding molecules larger than 50,000 Daltons, but with a pore system that allows good ingress and egress of molecules smaller than 35,000 Daltons. The pore system in these porous polymeric adsorbents is controlled by the method of synthesis so that 98% of the total pore volume is located in pores smaller than 300 Angstroms (?) in diameter with a working pore size range within 100 to 300 ? in diameter. The porous polymeric adsorbents of this invention are very selective for extracting midsize proteins, such as cytokines and ?2-microglobulin, from blood and other physiologic fluids while keeping the components required for good health such as cells, platelets, albumin, hemoglobin, fibrinogen, and other serum proteins intact.
    Type: Grant
    Filed: November 20, 2006
    Date of Patent: January 25, 2011
    Assignee: Cytosorbents, Inc.
    Inventors: Wei-Tai Young, Robert L. Albright, Thomas D. Golobish
  • Patent number: 7846650
    Abstract: Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of pro-inflammatory or anti-inflammatory stimulators or mediators. The devices, systems, and methods serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: December 7, 2010
    Assignees: Cytosorbents, Inc.
    Inventors: James A Brady, James F Winchester, Vadim Davankov, Maria Tsyurupa, Ludmila Pavlova, Frank M Norris, Peter J Quartararo, Jr., Jamie A Salsberg